Is Ruxolitinib a targeted drug?

Ruxolitinib is a targeted cancer drug sold under the brand names of Jakafi and Jakavi. It can be used to treat certain myeloproliferative tumors, such as myelofibrosis and polycythemia vera. Ruxolitinib is currently available as part of a clinical trial for another myeloproliferative tumor.

Targeted drugs such as ruxolitinib tablets can also be called cancer growth blockers. Cancer growth blockers block growth factors that trigger the division and growth of cancer cells. The active substance in ruxolitinib tablets Ruxolitinib works by blocking a gene important in blood cell production called JAK2. Before patients start treatment with ruxolitinib tablets, doctors will recommend that patients blood tests be tested for changes in the JAK2 gene. Two trials of oral ruxolitinib tablets in phase III controlled myelofibrosis studies showed significant benefit by reducing spleen size and alleviating debilitating symptoms.

Ruxolitinib tabletsThe original drug has been launched in China and is included in the scope of Class B medical insurance. It is limited to patients who meet the indications. Specification The price of each box of 5mg*60 tablets may be around RMB 3,000. The Turkish version of ruxolitinib tablets listed overseas, Specifications20mg*56 tablets, may be priced around RMB 8,000 per box (the price may fluctuate due to exchange rates). There are also ruxolitinib tablets produced in other countries. For example, the price of 5mg*50 tablets produced by Bangladesh Yaopin International may be around 1,400 yuan per box (the price may fluctuate due to exchange rates). Its pharmaceutical ingredients are basically the same as those of domestic and foreign original drugs.